- Conditions
- Juvenile Myoclonic Epilepsy
- Interventions
- JZP926 capsule, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 79
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
- Interventions
- Cannabidiol
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Downey, California • Long Beach, California + 22 more
- Conditions
- Dravet Syndrome
- Interventions
- zorevunersen, Sham Comparator
- Drug · Other
- Lead sponsor
- Stoke Therapeutics, Inc
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
- Conditions
- Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
- Interventions
- Soticlestat
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 56 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more
- Conditions
- Developmental and Epileptic Encephalopathy
- Interventions
- LP352
- Drug
- Lead sponsor
- Longboard Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 66 Years
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- Progressive Myoclonus Epilepsy Type 1, EPM1, CSTB-related Disease, Myoclonus Epilepsies, Progressive, Unverricht-Lundborg Disease, Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature, PME, Progressive Myoclonus-Epilepsies
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome
- Interventions
- Vatiquinone, Placebo
- Drug · Other
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- Up to 20 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- San Diego, California • Stanford, California • New Haven, Connecticut + 7 more
- Conditions
- Epilepsy
- Interventions
- Cannabidiol
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Dravet Syndrome
- Interventions
- STK-001 - Single Ascending Doses, STK-001 - Multiple Ascending Doses
- Drug
- Lead sponsor
- Stoke Therapeutics, Inc
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 18
- States / cities
- San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, Focal Seizures
- Interventions
- Turmeric
- Dietary Supplement
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 1 Year to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cyclin-Dependent Kinase-Like 5 Deficiency Disorder
- Interventions
- No intervention; observational
- Other
- Lead sponsor
- Loulou Foundation
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Aurora, Colorado • Norcross, Georgia + 6 more
- Conditions
- Lafora Disease
- Interventions
- ION283
- Genetic
- Lead sponsor
- Berge Minassian
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Dravet Syndrome
- Interventions
- Stiripentol
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 1 Year to 21 Years
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
- Interventions
- GWP42003-P
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 1 Month to 23 Months
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more
- Conditions
- Dravet Syndrome
- Interventions
- stiripentol
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 11 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Dravet Syndrome, Epileptic Encephalopathies Associated With SCN1A Mutations
- Interventions
- Stiripentol
- Drug
- Lead sponsor
- Cook Children's Health Care System
- Other
- Eligibility
- 6 Months to 18 Years
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2026
- U.S. locations
- 16
- States / cities
- San Diego, California • Stanford, California • Aurora, Colorado + 12 more
- Conditions
- CDKL5 Deficiency Disorder (CDD)
- Interventions
- Survey Instrument
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Dravet Syndrome
- Interventions
- ION337
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • Rochester, Minnesota • Durham, North Carolina + 2 more
- Conditions
- Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS)
- Interventions
- CBD: GT4 Transdermal Delivery System
- Drug
- Lead sponsor
- Alexander Rotenberg
- Other
- Eligibility
- 2 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox Gastaut Syndrome
- Interventions
- LP352, Placebo
- Drug
- Lead sponsor
- Longboard Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Downey, California + 24 more
- Conditions
- Juvenile Myoclonic Epilepsy
- Interventions
- Blood draw, Existing samples
- Other
- Lead sponsor
- King's College London
- Other
- Eligibility
- 10 Years to 40 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 3
- States / cities
- New York, New York • Columbus, Ohio
- Conditions
- Inherited Mitochondrial Disease
- Interventions
- Vatiquinone
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 14
- States / cities
- La Jolla, California • Stanford, California • New Haven, Connecticut + 10 more
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
- Interventions
- Specimen sample
- Diagnostic Test
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts